Trial Profile
Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose double-blind, placebo-controlled, parallel groups, international study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- 04 Feb 2021 Results of meta-analysis of 3 studies (EudraCT2004-002577-23; ISRCTN03554974; EudraCT2012-001666-15) assessing effects of agomelatine on anxious symptoms and functional impairment, published in the Advances in Therapy.
- 06 Sep 2011 Status changed from recruiting to completed based on reported results.
- 07 Jul 2011 New trial record